key: cord-0910268-b443rjyp
authors: Eales, O.; Page, A.; Tang, S. N.; Walters, C. E.; Wang, H.; Haw, D.; Trotter, A. J.; Le Viet, T.; Foster-Nyarko, E.; Prosolek, S.; Atchinson, C.; Ashby, D.; Cooke, G.; Barclay, W.; Donnelly, C. A.; O'Grady, J.; Volz, E.; The COVID-19 Genomics UK Consortium,; Darzi, A.; Ward, H.; Elliott, P.; Riley, S.
title: SARS-CoV-2 lineage dynamics in England from January to March 2021 inferred from representative community samples
date: 2021-05-14
journal: nan
DOI: 10.1101/2021.05.08.21256867
sha: 9d549d78b83442cc6ed3bbf18d0e4de365c3e31f
doc_id: 910268
cord_uid: b443rjyp

Genomic surveillance for SARS-CoV-2 lineages informs our understanding of possible future changes in transmissibility and vaccine efficacy. However, small changes in the frequency of one lineage over another are often difficult to interpret because surveillance samples are obtained from a variety of sources. Here, we describe lineage dynamics and phylogenetic relationships using sequences obtained from a random community sample who provided a throat and nose swab for rt-PCR during the first three months of 2021 as part of the REal-time Assessment of Community Transmission-1 (REACT-1) study. Overall, diversity decreased during the first quarter of 2021, with the B.1.1.7 lineage (first identified in Kent) predominant, driven by a 0.3 unit higher reproduction number over the prior wild type. During January, positive samples were more likely B.1.1.7 in younger and middle-aged adults (aged 18 to 54) than in other age groups. Although individuals infected with the B.1.1.7 lineage were no more likely to report one or more classic COVID-19 symptoms compared to those infected with wild type, they were more likely to be antibody positive 6 weeks after infection. Viral load was higher in B.1.1.7 infection as measured by cycle threshold (Ct) values, but did not account for the increased rate of testing positive for antibodies. The presence of infections with non-imported B.1.351 lineage (first identified in South Africa) during January, but not during February or March, suggests initial establishment in the community followed by fade-out. However, this occurred during a period of stringent social distancing and targeted public health interventions and does not immediately imply similar lineages could not become established in the future. Sequence data from representative community surveys such as REACT-1 can augment routine genomic surveillance.

Since the emergence of SARS-CoV-2 in late 2019 [1] there has been a continuous accumulation of mutations leading to a genetically diverse phylogeny [2] . Although most mutations are neutral, having no effect on the epidemiology of the virus, some have been found to affect transmissibility [3] and antigenicity [4] , and have arisen on multiple occasions in independent lineages [5] . Lineages that are judged likely to have increased transmissibility or severity relative to current dominant lineages in the UK are termed 'Variants of Concern' (VOC) [6] [7] [8] .

The B.1.1.7 lineage (Pango nomenclature [9] , used for the rest of the paper) VOC was first detected in Kent, England 20th September 2020 [10, 11] . Since its emergence, it has risen to become the dominant lineage in the United Kingdom (UK), and has increased in frequency in many other countries [12] . Previous studies have estimated that this lineage is more transmissible than previously dominant lineages, as measured by the reproduction number (R) [6, 13] .

The B.1.351 lineage was first detected in South Africa [7] in October 2020 and by March 2021 there had been 291 detections in the UK [14] . The lineage is associated with the E484K single nucleotide polymorphism (SNP) in the spike protein, which has been found to reduce the neutralizing activity of post-vaccination sera [15] , triggering fears of lowered vaccine efficacy. This SNP has also been detected in a cluster of B.1.1.7 cases In England, predominantly in the South West [16] . Two further lineages, A.23.1 [17] and B.1.525, are currently described as 'Variants under Investigation (VUI)' [18] due to the presence of several SNPs of biological significance. Both of these lineages have been detected in low numbers in the United Kingdom [19, 20] . A cluster of A.23.1 that exhibits the E484K SNP has been detected in Liverpool, England [16] .

Extensive genomic surveillance has been undertaken in the UK by the COVID-19 Genomics UK Consortium (COG-UK) [21] . From its inception in March 2020 to the end of March 2021, COG-UK sequenced over 320,000 positive cases [22] representing 45% [23] of all uploaded sequences to GISAID, a global open-access database for coronavirus and influenza genomic data [24] , with UK coverage of all detected samples varying from 2.5% [25] to 17 .1% [26] . Samples included in COG-UK data are taken from several different sources: hospital cases, routine community surveillance, outbreak investigations and border screening.

The REal-time Assessment of Community Transmission study obtains throat and nose swabs from a random sample of the population in England (REACT-1) [27] . From the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint beginning of May 2020 to the end of March 2021, there were 10 rounds of REACT-1 with between 140,000 and 175,000 swab tests each round. Here we present the results of the genome sequencing performed on the positive swabs in early 2021, from round 8 (6 January -22 January), round 9 (4 February -23 February) and round .

In round 8 we were able to reliably determine lineages for 1,088 out of 2,282 positive samples, of which 83% (80%, 85%, n=898) were the B. Fitting a logistic regression model to whether a sample was identified as B.1.1.7 or not allowed us to estimate a difference in daily growth rate between B.1.1.7 and all other lineages of 0.049 (0.034, 0.067) ( Figure 1 ). This corresponds to an additive R advantage of 0.31 (0.21, 0.42), (assuming a mean generation time of 6.29 days, see Methods) and suggests a smaller difference than estimates based on sequences collected during November and December 2020 in england (between 0.4 and 0.7) [28] . Our lower estimate of the difference in R at a later time is consistent with a decreasing selection coefficient reported in the earlier study. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint North West (Figure 2 ). This pattern is consistent with prior observations of B.1.1.7 lineage emerging in the South East [11] leading to earlier seeding events in the South of England.

By February (round 9), spatial heterogeneity was substantially reduced with B.1.1.7 accounting for over 80% of lineages in all regions.

During round 8 there were higher proportions of B.1.1.7 in 18-to 54-year olds compared with other age groups (Figure 1 ). Using a logistic regression model (see Methods), this pattern was not explained by regional confounding (Figure 1 ). In contrast, for round 9, albeit based on fewer positive samples, the proportion of B.1.1.7 was similar in all age groups.

Case data from November and December 2020 show a higher proportion of B.1.1.7 in school aged children than in other age groups [6] , however schools were open for face-toface teaching for all children during this time unlike during our study when school attendance was greatly limited [29, 30] .

The percentage of people infected with B.1.1.7 reporting no symptoms ( describe only the lower part of the severity pyramid --the fraction of those infected who develop symptoms --and contrast with a previous study using clinical cases as the denominator which found that the B.1.1.7 lineage caused more severe illness with increased relative mortality [31] . However, other previous work found no difference in symptomatology for B.1.1.7 against other circulating lineages [32] . We also note that participants in REACT-1

were not followed up, other than a small subset in round 8. Therefore, some participants will have developed symptoms after filling out the questionnaire.

Quantitative PCR Ct values for N and E gene targets were lower for the B. with a decrease in Ct of 1 corresponding to an approximate twofold increase in viral load [33] . This result matches earlier work that suggested the B.1.1.7 lineage has higher viral . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint loads than other circulating lineages [34] . However, it is possible that both analyses have been influenced by the high growth rate of B.1.1.7 during its emergence relative to other lineages which could lead to a difference in the observed distribution generated by differences in the average time since infection [35] . Also, given that our sample workflow ensures that lower Ct values are more likely to receive a lineage designation, a lower intrinsic Ct value for B.1.1.7 could have led to an overestimated proportion of B.1.1.7 in the community.

Antibody positivity six weeks after the initial swab test, assessed using a lateral flow immunoassay [36] , was higher in those infected with B.1. 

Though only a small number of B.1.351, B.1.525, A.23.1 and B.1.1.7+E484K were detected in January, because of the random sampling strategy used for REACT-1, we can estimate their prevalence with well-quantified uncertainty (Supplementary Table 6 Table 6 ), suggesting that these lineages were already established in the community during January 2021. Additionally, none of the individuals infected with these lineages who answered the question reported that they had been abroad in the previous two weeks (Supplementary Table 7) . However, not all of the participants who tested positive for a VOC or VUI answered the question about recent travel (one did not for B.1.525, one did not for A.23.1). Also, the sequences of some of the REACT-1 samples grouped very closely with other English isolates when compared to a representative global subsample of the lineage (e.g. ARCH-000045H2 for B.1.351 in Figure   4 and all isolates in Figure 5 ), further suggesting that significant local transmission was occurring at that time.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 8 ). The converse is seen in publicly available sequence data form community testing [37] have been seen in some regions of Europe [12, 14, 39] and in Africa [7] .

Spatial patterns of observed VOCs and VOIs may be driven partly by geographical variation in the frequency with which people travel abroad. The overall proportion of participants reporting travel abroad in the past two weeks ( Figure 6 , Supplementary Table 9) in round 5 (September) was 1.63% (1.56%, 1.69%), but declined to 0.49% (0.46%, 0.53%) in round 8 (January), 0.11% (0.09%, 0.13%) in round 9 (February), and 0.10% (0.08%, 0.12%) in round 10 (March). London had the highest proportion and the South East the second highest for all rounds ( Figure 6 ). We estimated that over 55% of the people returning from abroad to England during rounds 8, 9 and 10 were in London and the South East (Supplementary Table 9 ). Sub-regionally ( Figure 6 and Supplementary Figure 5 ) we see that during round 5 (September) there was little spatial heterogeneity in the proportion of people who had been . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our study has limitations. During round 8 a subsample of participants testing positive also undertook two additional swab tests. The sequencing results from these additional swabs indicates possible misallocation of samples to participants. Though not all of these samples contained sufficient viral copies for successful sequencing (high Ct) or not enough physical volume in the sample, we were able to sequence multiple swab tests for some participants.

These extra sequences, when a lineage was determined, allowed augmentation of the data for round 8 for some of the participants whose first test was unable to be sequenced or have is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint have been removed from the main analysis. This points to some potential sample mix-ups caused by manual cherry picking in the diagnostic pipeline; however, these errors are only likely to affect the most prevalent lineages, specifically B.1.1.7 and B.1.177.

The success of B.1.1.7 against the prior wild type and more recent variants during the first three months of 2021 in England during lockdown does not necessarily mean that future imported variants such as B.1.617.2 (first identified in India) will not succeed [40] . The immune landscape [41] against SARS-CoV-2 in the UK is changing rapidly because of high uptake of effective vaccines across a broad range of age groups. On the other hand, as stringent interventions during lockdown are eased, the potential for person-to-person contact and overall average transmissibility of SARS-CoV-2 in England will increase.

Methods for the REACT-1 study have been described previously [27] . Since May 2020, there have been 10 rounds of data collection approximately every month with between 140,000 and 175,000 swab tests completed over a 2-3 week period by a random subset of the population of England aged 5 and over. From round 8 onwards, all positive tests with a low N-gene Ct value (less than 34 used initially, but criteria changed midway through round 9 to less than 32 due to high rate of sequencing failure in those with N-gene Ct>32 [approx 88%]) and a high enough volume were sent for genome sequencing (Public Health England Research Ethics Governance Group (reference: R&D NR0195)). Extracted RNA was amplified using the ARTIC protocol [43] with sequencing libraries prepared using CoronaHiT [44] , and sequenced on the Illumina NextSeq 500 platform. Each set of 96 samples included one positive and one negative control. Raw sequencing data were analysed using the ARTIC bioinformatic pipeline [45] and uploaded to CLIMB [46] for further analysis.

From the genome sequences lineages are assigned using a machine learning based assignment algorithm, PangoLEARN [47] (database version 2021-04-28) with lineage assignment following the Pangolin nomenclature [9] . Not all obtained sequences were of a high enough quality for a lineage to be determined and so are not included in the analysis.

Further, samples in which less than 50% of bases were covered were excluded from the analysis. A diagram showing how many positive samples were sequenced and how many had a lineage determined is shown in Supplementary Figure 1 Following lineage allocation by the algorithm, each sequence was then also investigated individually, particularly for the presence of lineage defining SNPs. This allowed for lineages that were too low quality to call by PangoLEARN to be manually assigned. This occurred twice, once for a B.1 lineage call that exhibited six of 14 B.1.351 lineage defining mutations . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. 95% confidence intervals in lineage proportions were calculated assuming a binomial distribution using the Wilson method [51] , which is preferred when the number of positive outcomes is small [52] . Differences in multinomial proportions between rounds were assessed using a multinomial goodness-of-fit test implemented using the XNomial package in R [53] . Table 1 and Supplementary Table 2) , and the population size of England and each region [55] Relative differences in growth rates between two lineages were estimated by fitting a Bayesian logistic regression model to the binary lineage outcome. This was converted into an additive difference ( ) in R through the equation

, with the assumption ൌ 1 ൈ [56] where r is the growth rate of a lineage and is the mean generation time, assumed to be 6.29 days [57] for both lineages.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint

Smoothed spatial estimates of the relative proportion of two lineages were estimated using a Bayesian generalised-linear mixed-effects model implemented in the R package glmmfields [58] . We included 25 knots to describe the spatial processes and random spatial effects were assumed to follow a multivariate-t distribution. Priors of the model were chosen to be uninformative.

A subsample of positive participants in round 8 underwent a lateral flow immunoassay [36] approximately 6 weeks after their initial swab test. Differences in raw antibody positivity by lineages were assessed using logistic regression, with a binomial likelihood using a logit link 

The study was funded by the Department of Health and Social Care in England. Sequencing was provided through funding from COG-UK.

The authors have declared no competing interest.

The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group (reference: R&D NR0195). This study was conducted as part of 

Assembled/consensus genomes are available from GISAID subject to minimum quality control criteria. Raw reads are available from European Nucleotide Archive (ENA). All genomes, phylogenetic trees, and basic metadata are available from the COG-UK consortium website (https://www.cogconsortium.uk). For confidentiality reasons, extended metadata are not publicly available, however some may be available upon request.

Correspondence and requests for materials should be addressed to Steven Riley and Paul Elliott, s.riley@imperial.ac.uk, p.elliott@imperial.ac.uk, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint Titles for Supplementary Tables 1 to 10 are included below with the tables themselves in this spreadsheet. Supplementary Figures 1 to 5 are included below. Full list of COG-UK author's names and affiliations are available in this spreadsheet.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint Tables and figures   Table 1 . Results of Gaussian regression with either E-gene or N-gene Ct value as the observation and lineage as the explanatory variable.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Table 9 . Proportion of participants that reported being abroad two weeks prior to their swab test by region and by round, estimated average number of people who had been abroad in the previous two weeks by region and round, and the overall percentage of people returning from abroad that were in each region of England. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.08.21256867 doi: medRxiv preprint

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Genetic Variation and Evolution of the 2019 Novel Coronavirus

Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. bioRxiv. medRxiv

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

PHE investigating a novel variant of COVID-19

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera

PHE statement on Variant of Concern and new Variant Under Investigation

A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic. medRxiv

Variants: distribution of cases data

COVID-19 Genomics UK (COG-UK) consortiumcontact@cogconsortium.uk. An integrated national scale SARS-CoV-2 genomic surveillance network

Alarming COVID variants show vital role of genomic surveillance

disease and diplomacy: GISAID's innovative contribution to global health

Summary report: COG-UK geographic coverage of SARS-CoV-2 sample sequencing

REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

New guidance for schools, colleges and early years

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature

The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility. bioRxiv. medRxiv

Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools

Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein. bioRxiv. medRxiv

Estimating epidemiologic dynamics from cross-sectional viral load distributions. medRxiv

SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study

COG-UK Mutation Explorer

Surge testing for new coronavirus (COVID-19) variants

RAPID RISK ASSESSMENT

Scientific Advisory Group for Emergencies. PHE: Investigaton of novel SARS-CoV-2 variants of concern (England) -Technical briefing 9

Cohort Profile: A study of influenza immunity in the urban and rural Guangzhou region of China: the Fluscape Study

Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis

nCoV-2019 sequencing protocol v3 (LoCost)

CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes

A Nextflow pipeline for running the ARTIC network's field bioinformatics tools. Github

CLIMB (the Cloud Infrastructure for Microbial Bioinformatics): an online resource for the medical microbiology community

Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN). Github

Standardised Variant Definitions: A repository containing the up-to-date lineage definitions for variants of concern (VOC) and variants of interest (VUI) as curated by Public Health England. Github

IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies

Probable Inference, the Law of Succession, and Statistical Inference

Interval Estimation for a Binomial Proportion

Exact Goodness-of-Fit Test for Multinomial Data with Fixed Probabilities

REACT-1 round 9 final report: Continued but slowing decline of prevalence of SARS-CoV-2 during national lockdown in England in

Population estimates for the

How generation intervals shape the relationship between growth rates and reproductive numbers

Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts

Black swans in space: modeling spatiotemporal processes with extremes